MBX Biosciences, Inc.
MBX
$8.70
$0.070.81%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 53.04% | 47.55% | 104.61% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 79.19% | 108.04% | 109.11% | ||
| Operating Income | -79.19% | -108.04% | -109.11% | ||
| Income Before Tax | -78.53% | -108.43% | -107.38% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -78.53% | -108.43% | -107.38% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -78.53% | -108.43% | -107.38% | ||
| EBIT | -79.19% | -108.04% | -109.11% | ||
| EBITDA | -79.16% | -108.27% | -109.57% | ||
| EPS Basic | 70.37% | -64.32% | -47.77% | ||
| Normalized Basic EPS | 70.37% | -64.31% | -47.76% | ||
| EPS Diluted | 70.37% | -64.32% | -47.77% | ||
| Normalized Diluted EPS | 70.37% | -64.31% | -47.76% | ||
| Average Basic Shares Outstanding | 502.57% | 26.84% | 40.35% | ||
| Average Diluted Shares Outstanding | 502.57% | 26.84% | 40.35% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||
